Display Settings:

Format

Send to:

Choose Destination

    J Pediatr. 2001 May;138(5):763-6.

    New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment.

    Mukamel M, Horev G, Mimouni M.

    Pediatric Rheumatology Unit, the Pediatric Imaging Department, and Day Care Unit, Schneider Children's Medical Center of Israel, Petah Tiqva, Israel.

    Milk of calcium developed in 2 children with juvenile dermatomyositis. The fluid of the collection contained macrophages, interleukin-6, IL-1, and tumor necrosis factor. The patient who had dystrophic calcinosis had a dramatic improvement with the introduction of alendronate. These findings suggest that calcinosis of juvenile dermatomyositis may be mediated by activated macrophages and that alendronate can be an effective treatment for this condition.

    PMID: 11343059 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read Click here to read

    Patient drug information

    • Alendronate (Fosamax®, Fosamax Plus D®)

      Alendronate is used to treat and prevent osteoporosis (a condition in which the bones become thin and weak and break easily) in women who have undergone menopause ('change of life,' end of menstrual periods) and to treat...